Cargando…

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor

Downstream A(3) receptor signalling plays an important role in the regulation of cell death and proliferation. Therefore, it is important to determine the molecular pathways involved through A(3) receptor stimulation. The phosphatidylinositide-3-OH kinase (PI3K)/Akt and the Raf/mitogen-activated pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merighi, Stefania, Benini, Annalisa, Mirandola, Prisco, Gessi, Stefania, Varani, Katia, Leung, Edward, MacLennan, Stephen, Baraldi, Pier Giovanni, Borea, Pier Andrea
Formato:	Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2006
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2096659/ https://www.ncbi.nlm.nih.gov/pubmed/18404465 http://dx.doi.org/10.1007/s11302-006-9020-4

Ejemplares similares

Adenosine and lymphocyte regulation
por: Gessi, Stefania, et al.
Publicado: (2007)

Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors
por: Gessi, Stefania, et al.
Publicado: (2006)

Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets
por: Pasquini, Silvia, et al.
Publicado: (2022)

A(1) Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic?
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12 Cells Can Be Shifted towards a Neuroprotective Role through A(1)AR Positive Allosteric Modulation
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields
por: Varani, Katia, et al.
Publicado: (2017)

Pharmacology of Adenosine Receptors: Recent Advancements
por: Vincenzi, Fabrizio, et al.
Publicado: (2023)

A(2A) Adenosine Receptor: A Possible Therapeutic Target for Alzheimer’s Disease by Regulating NLRP3 Inflammasome Activity?
por: Merighi, Stefania, et al.
Publicado: (2022)

An Open Question: Is the A(2A) Adenosine Receptor a Novel Target for Alzheimer’s Disease Treatment?
por: Merighi, Stefania, et al.
Publicado: (2021)

A(2A) Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease
por: Gessi, Stefania, et al.
Publicado: (2021)

The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells
por: Vincenzi, Fabrizio, et al.
Publicado: (2012)

Role and Function of A(2A) and A(3) Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis
por: Ravani, Annalisa, et al.
Publicado: (2017)

Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy
por: Fernandez, Mercedes, et al.
Publicado: (2023)

Caffeine for Prevention of Alzheimer’s Disease: Is the A(2A) Adenosine Receptor Its Target?
por: Merighi, Stefania, et al.
Publicado: (2023)

Inhibition of A(2A) Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455
por: Gessi, Stefania, et al.
Publicado: (2017)

A(2A) Adenosine Receptors Are Differentially Modulated by Pharmacological Treatments in Rheumatoid Arthritis Patients and Their Stimulation Ameliorates Adjuvant-Induced Arthritis in Rats
por: Vincenzi, Fabrizio, et al.
Publicado: (2013)

Pulsed Electromagnetic Fields Increased the Anti-Inflammatory Effect of A(2A) and A(3) Adenosine Receptors in Human T/C-28a2 Chondrocytes and hFOB 1.19 Osteoblasts
por: Vincenzi, Fabrizio, et al.
Publicado: (2013)

Adenosinergic System Involvement in Ischemic Stroke Patients’ Lymphocytes
por: Pasquini, Silvia, et al.
Publicado: (2020)

Pathophysiological Role and Medicinal Chemistry of A(2A) Adenosine Receptor Antagonists in Alzheimer’s Disease
por: Merighi, Stefania, et al.
Publicado: (2022)

Anxiolytic properties of A(1) adenosine receptor PAMs
por: Vincenzi, Fabrizio, et al.
Publicado: (2016)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Adenosine and Inflammation: Here, There and Everywhere
por: Pasquini, Silvia, et al.
Publicado: (2021)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

The Role of Adenosine Receptors in Psychostimulant Addiction
por: Ballesteros-Yáñez, Inmaculada, et al.
Publicado: (2018)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

A(2A) adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus
por: Bortoluzzi, Alessandra, et al.
Publicado: (2016)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications
por: Pasquini, Silvia, et al.
Publicado: (2022)

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
por: Knight, Thomas, et al.
Publicado: (2014)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

Targeting Cadherin-17 Inactivates Ras/Raf/MEK/ERK Signaling and Inhibits Cell Proliferation in Gastric Cancer
por: Lin, Zhaohu, et al.
Publicado: (2014)

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
por: Kinsey, Conan G., et al.
Publicado: (2019)

Design, Synthesis, and Antileukemic Evaluation of a Novel Mikanolide Derivative Through the Ras/Raf/MEK/ERK Pathway
por: Rao, Qing, et al.
Publicado: (2022)

Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa
por: Jafari, Meryem, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i10bf0apojjov8u68gmoqrtd9g